Search results
Psychedelic Tx: What Meaningful Informed Consent Looks Like
Medscape· 7 days agoThe US Food and Drug Administration has designated psilocybin and 3,4-methylenedioxymethamphetamine...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 4 days agoThis is the latest of several collaborations for Compass, intended to better understand a range of potential approaches to deliver COMP360 to patients in different care settings.
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 3 days agoPhase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase ...
...) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for ...
FOX 5 San Diego· 6 days agoNRX-101 is first oral antidepressant to show 33% advantage in sustained remission in suicidality (not statistically significant at this sample size) and 75% advantage in relief from Akathisia ...
MagVenture Announces Collaboration with Magnus Medical to Bring the SAINT® Neuromodulation System to...
FOX 5 San Diego· 5 days agoSAINT therapy will enable patients to receive a quick, highly effective treatment for Major Depressive Disorder (MDD), especially in the acute setting where TMS has been limited ...
Compass Pathways partners with Journey Clinical for psilocybin research By Investing.com
Investing.com· 6 days ago-based psychedelic-assisted psychotherapy platform. The partnership aims to develop a scalable...
May is Mental Health Awareness Month. Experts and Patients Available for Interviews on Trending...
Newswise· 4 days agoMore than one in five adults in the U.S. lives with mental illness, and a quarter of U.S. adults have acute mental illness, which includes major depression and bipolar disorder ...
NRX-101 shows promise in bipolar depression trial By Investing.com
Investing.com· 6 days agoNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has reported findings from a clinical trial suggesting that...
Research shows how low intensity light applied to brain-gut axis can fight the effects of chronic...
Medical Xpress· 4 days agoNow, a study published in the Journal of Affective Disorders reveals how photobiomodulation applied to the brain-gut axis is effective in recovering some cognitive alterations and sequelae caused ...
Neurocrine bags FDA approval for new ‘sprinkle’ Ingrezza formulation
Pharmaceutical Technology via Yahoo Finance· 5 days agoLast month, Neurocine released positive topline data from the Phase II SAVITRI trial that evaluated...